New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System
Rhea-AI Summary
MiniMed (Nasdaq: MMED) reported a randomized crossover trial showing virtually identical glycemic outcomes using the MiniMed 780G system with either Simplera Sync or Abbott’s Instinct sensor in 24 adults with type 1 diabetes.
Time in Range was about 80%, HbA1c about 6.7–6.8%, with no DKA or severe hypoglycemia. Real-world data from over 20,000 U.S. users also showed strong glycemic control across Guardian 4 and Instinct sensors, supporting the central role of the SmartGuard algorithm.
AI-generated analysis. Not financial advice.
Positive
- Randomized crossover trial (N=24) showed ~80% Time in Range with both sensors
- HbA1c around 6.7–6.8% across sensors using MiniMed 780G system
- No reported diabetic ketoacidosis, severe hypoglycemia, or unanticipated device effects
- Real-world data on 20,245 users showed 74.8–80.5% Time in Range
- High Time in Auto Mode up to 97.5% in real-world analysis
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
No peers in the provided dataset showed concurrent momentum, suggesting the 6.8% move was company-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Earnings date set | Neutral | +5.7% | Announced schedule for Q4 and full-year 2026 earnings release and webcast. |
| Mar 18 | FDA clearance pump | Positive | -0.2% | FDA cleared MiniMed Flex™, a smaller smartphone-controlled pump using SmartGuard™. |
| Mar 09 | IPO completion | Positive | +1.8% | Closed IPO of 28,000,000 shares at $20.00, raising ~$538M in net proceeds. |
Recent positive operational milestones have seen mixed follow-through, with FDA clearance showing a slight negative reaction while IPO and event scheduling were met with gains.
Over recent months, MiniMed reported its IPO, FDA clearance for MiniMed Flex™, and scheduled its first post-IPO earnings date. The IPO priced at $20.00 per share with a $538 million net proceed, and the Flex clearance added a key smartphone-controlled pump to the portfolio. Market reactions have varied: the IPO and earnings-date announcement saw gains of 1.83% and 5.7%, while the Flex clearance drew a modest -0.24% move, indicating inconsistent trading responses to otherwise constructive news.
Market Pulse Summary
This announcement highlighted that the MiniMed 780G SmartGuard™ algorithm delivered virtually identical glycemic outcomes across different sensors, with Time in Range around 80% and strong Auto Mode use. Real-world data on 20,245 users reinforced the algorithm’s central role. In context of prior milestones such as the IPO and FDA clearance of MiniMed Flex™, this adds evidence of clinical robustness, while investors may watch upcoming earnings and further usage data for additional confirmation.
Key Terms
automated insulin delivery medical
hbA1c medical
diabetic ketoacidosis medical
real-world evidence medical
algorithm technical
AI-generated analysis. Not financial advice.
Randomized crossover trial reinforces SmartGuard™ algorithm as key driver of automated insulin delivery performance
Instinct (N=24) | Simplera Sync™ (N=24) | |
Time in Range | 79.1 % | 80.6 % |
HbA1c | 6.7 % | 6.8 % |
Mean Sensor Glucose | 137.9 mg/dL | 139.5 mg/dL |
Time in Auto Mode | 90.0 % | 92.6 % |
"These results underscore an important principle in automated insulin delivery, which is that the intelligence of the algorithm is what ultimately drives glycemic outcomes," said Principal Investigator Amir Tirosh, Director of the Division of Endocrinology, Diabetes, and Metabolism at Sheba Medical Center and Professor of Medicine at
Twenty-four adult participants with type 1 diabetes were randomized to use either the Simplera Sync™ or Instinct sensor for a six-week period, then crossed over to the alternate sensor for an additional six weeks. Each crossover period utilized a new insulin pump to eliminate algorithm memory carryover effects.
Both sensors maintained strong Time in Range during the study period, exceeding international consensus targets for glycemic control as defined by the American Diabetes Association.2 No cases of diabetic ketoacidosis (DKA), severe hypoglycemia, or unanticipated device effects were reported during the study.
Real-World Evidence Reinforces Clinical Findings
These results build on preliminary real-world evidence on 4,364
An updated real-world analysis of over 20,000
Guardian™4 sensor Overall | Instinct sensor Overall | Guardian™ 4 sensor | Instinct sensor w/ Recommended Settings | |
Number of Individuals | 20245 | 20245 | 8558 | 8558 |
Time in Range (70–180 mg/dL) | 74.8 % | 76.6 % | 78.7 % | 80.5 % |
GMI | 6.9 % | 6.9 % | 6.8 % | 6.7 % |
Time in Auto Mode | 90.0 % | 94.9 % | 93.2 % | 97.5 % |
"This data provides compelling clinical validation of what we've always believed — that the power of our system lies in the intelligence of our SmartGuard™ algorithm," said Que Dallara, CEO of MiniMed. "This growing body of evidence gives people living with diabetes the confidence to choose a sensor from our portfolio that best fits their lifestyle. We're relentlessly focused on advancing the science behind automated insulin delivery and building a full-stack insulin delivery ecosystem that makes diabetes management simpler, more personalized, and increasingly hands-free."
About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.
Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's filings with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
1 Laron-Hirsch, M., et al. Glycemic concordance of Simplera Sync™ and Instinct sensors in MiniMed™ 780G system users: A randomized crossover feasibility study. Diabetes Technology and Therapeutics. DOI:10.1177/15209156261449884
2 American Diabetes Association Professional Practice Committee; 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care 1 January 2025; 48 (Supplement_1): S128–S145. https://doi.org/10.2337/dc25-S006
3 Medtronic data on file: MiniMed 780G data uploaded voluntarily by 4,364 eligible users to CareLink Personal, from 2 January 2020 to 31 January 2026
4 Shah VN, et al. Performance of a newly introduced sensor with an AID system: A real-world analysis. Presented at: International Conference on Advanced Technologies & Treatments for Diabetes; March 11-14, 2026;
5 Data on file.
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-study-showed-consistent-glycemic-outcomes-across-sensors-integrated-with-minimed-780g-system-302778917.html
SOURCE MiniMed